PMID: 6983500Sep 1, 1982Paper

Comparative trial of trimethoprim and co-trimoxazole in recurrent urinary infections

Infection
W BrumfittR A Gargan

Abstract

Eighty-nine patients with a history of recurrent urinary infection who required immediate treatment for significant bacteriuria were treated with either trimethoprim (300 mg at night) or with the standard course of co-trimoxazole (two tablets 12-hourly) for seven days. Cure rates one week after the end of treatment were 74.4% and 80.4%, respectively. During the following month the relapse rate was lower in the group given trimethoprim than among those who had received co-trimoxazole. Consequently, the cure rates six weeks after the start of treatment were 71.4% in the trimethoprim group and 58.5% in the co-trimoxazole group. These results suggest that in this type of patient, it may be possible to reduce the incidence of bacteriological relapse by giving antibiotics in larger doses and at less frequent intervals than are at present generally recommended.

References

Nov 1, 1979·Journal of Medical Microbiology·P B Crichton, D C Old
Sep 1, 1978·Journal of Clinical Pathology·S G AmyesJ T Smith
Feb 1, 1976·Journal of Clinical Pathology·D Greenwood, F O'Grady
Sep 1, 1975·The Journal of Antimicrobial Chemotherapy·R N Grüneberg
Feb 1, 1974·Journal of Clinical Pathology·E L LewisR W Lacey
Mar 1, 1980·The Journal of Antimicrobial Chemotherapy·J CopperJ M Hamilton-Miller
Apr 1, 1981·Journal of Clinical Pathology·J M Hamilton-MillerW Brumfitt

❮ Previous
Next ❯

Citations

Oct 1, 1986·The Journal of Hygiene·V Damjanovic, E Whitfield
Apr 15, 2008·The Journal of Antimicrobial Chemotherapy·Karin Tegmark WisellChristian G Giske
Feb 1, 1984·Antimicrobial Agents and Chemotherapy·W Brumfitt, J M Hamilton-Miller
Dec 1, 1989·Antimicrobial Agents and Chemotherapy·J M Hamilton-Miller
Feb 1, 1994·Journal of Chemotherapy·W Brumfitt, J M Hamilton-Miller
Nov 24, 2019·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·P Mabboux, B Rouveix

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.